Claims
- 1. A method for preparing a variant polynucleotide having a different nucleotide sequence from at least two parent polynucleotides comprising;
preparing at least one heteroduplex between at least said two parent polynucleotides, cleaving at least one polynucleotide strand in said heteroduplex at a mismatch site to form a cleavage site, replacing at least one nucleotide on at least one polynucleotide strand at or near the cleavage site, wherein at least one of said polynucleotide strands has a different nucleotide sequence from either of said at least two parent polynucleotides.
- 2. The method of claim 1 wherein the polynucleotides forming a heteroduplex are circular.
- 3. The method of claim 2 wherein said preparing is performed in vitro and said cleaving and said replacing are performed in vivo.
- 4. The method of claim 1 herein the heteroduplex polynucleotide sequence contains a gene.
- 5. The method of claim 4 wherein the heteroduplex polynucleotide sequence is a genome.
- 6. The method of claim 4 wherein the heteroduplex polynucleotide sequence is a region within a polynucleotide molecule of greater than about 100 bp.
- 7. The method of claim 1 wherein at least three parental polynucleotides are used.
- 8. The method of claim 1 wherein a plurality of variant polynucleotides are formed.
- 9. A method for obtaining a polynucleotide sequence encoding a desired functional property comprising;
preparing at least one heteroduplex from at least two parent polynucleotides; cleaving at least one polynucleotide strand in said heteroduplex at a mismatch site to form a cleavage site, replacing at least one nucleotide on at least one polynucleotide strand at or near the cleavage site, wherein a plurality of variant polynucleotide strands are formed which have different nucleotide sequences from either of said at least two parent polynucleotides, and screening or selecting a population of variants for the desired functional property.
- 10. The method of claim 9 further comprising;
forming a second heteroduplex containing at least one variant polynucleotide strand, cleaving at least one polynucleotide strand in said second heteroduplex at a mismatch site to form a cleavage site, replacing at least one nucleotide on at least one polynucleotide strand at or near the cleavage site, wherein a plurality of variant polynucleotide strands are formed which have different nucleotide sequences from either parent polynucleotides present in said second heteroduplex, and screening or selecting a population of variants for the desired functional property.
- 11. The method of claim 9 further comprising converting said variant polynucleotide to RNA before said screening or selecting.
- 12. The method of claim 9 further comprising translating said variant polynucleotide or an RNA transcribed therefrom to produce a polypeptide and wherein said screening or selecting is performed on said polypeptide.
- 13. A method of identifying a reasserted DNA molecule with a desired functional property, comprising:
a) providing at least one single-stranded modified polynucleotide, which single-stranded modified polynucleotide, or a complementary strand thereto has or encodes the desired functional property, wherein said modified polynucleotide is capable of hybridization but not amplification; b) providing one or a plurality of non-identical single-stranded DNA molecules capable of hybridizing to the single-stranded modified polynucleotide, wherein said DNA molecules have or encode at least one additional variant; contacting the single-stranded modified polynucleotide with at least one single-stranded DNA molecule of step (b), thereby producing an annealed DNA molecule; incubating the annealed DNA molecule with a mismatch endonuclease, proofreading enzyme and a ligase, thereby producing a recombined DNA strand annealed to the single stranded modified polynucleotide; and screening or selecting the population of reasserted DNA molecules to identify those that encode the desired functional property, thereby identifying one or more DNA molecules(s) that encode a polypeptide with the desired functional property.
- 14. The method of claim 13 further comprising amplifying the reasserted DNA strand under conditions wherein the modified polynucleotide is not amplified, thereby producing a population of reassorted DNA molecules before said screening or selecting.
- 15. The method of claim 13 wherein said modified polynucleotide contains uracil.
- 16. A method of identifying a recombined DNA molecule with a desired functional property, comprising:
forming an annealed double stranded molecule between at least a. at least one single-stranded modified polynucleotide, which single-stranded modified polynucleotide, or a complementary strand thereto, wherein the modified polynucleotide is capable of hybridization but not amplification, and b. at least one non-identical single-stranded DNA capable of hybridizing to the single-stranded modified polynucleotide, wherein said DNA molecules have or encode at least one additional variant; cleaving at least the DNA strand of the annealed double stranded molecule to form a cleavage site, and replacing a nucleotide at or near the cleavage site, thereby producing a recombined DNA strand annealed to the modified polynucleotide; wherein said recombined DNA strand has a different nucleotide sequence from either polynucleotide of said annealed double stranded molecule, and screening or selecting the population of recombined DNA molecules to identify those that have or encode the desired functional property, thereby identifying one or more DNA molecules(s) that have or encode the desired functional property.
- 17. The method of claim 16 further comprising amplifying the recombined DNA strand under conditions wherein the modified DNA molecule is not amplified, thereby producing a population of recombined DNA molecules, before said screening or selecting.
- 18. The method of claim 16 wherein the cleaving is at a mismatch site.
- 19. The method of claim 16 wherein said modified polynucleotide contains uracil.
- 20. A composition for a method of making sequence variants in vitro from at least one heteroduplex polynucleotide where said heteroduplex has at least two non-complementary nucleotide base pairs, said composition comprises effective amounts of an agent or agents with exonuclease activity, polymerase activity and mismatch strand cleavage activity.
- 21. The composition of claim 20 further comprising a ligase activity.
- 22. The composition for a method of making sequence variants in vitro from at least one heteroduplex polynucleotide where said heteroduplex has at least two non-complementary nucleotide base pairs, said composition comprises effective amounts of an agent or agents with 3′ to 5′ proofreading exonuclease activity, polymerase activity and strand cleavage activity.
- 23. The composition of claim 22 further comprising a ligase activity.
- 24. A kit used for making sequence variants in vitro from at least one heteroduplex polynucleotide where said heteroduplex has at least two non-complementary nucleotide base pairs, wherein said kit comprises a plurality of vessels containing an effective amount of an agent or agents with exonuclease activity, polymerase activity and strand cleavage activity.
- 25. The kit of claim 24 further comprising an agent or agents having a ligase activity.
- 26. A nicked circular heteroduplex which has at least two non-complementary nucleotide base pairs and a nick located at at least one of the two non-complementary nucleotide base pairs.
- 27. The nicked circular heteroduplex of claim 26 wherein a nick is located at least two of said at least two non-complementary nucleotide base pairs.
- 28. A method for altering the length of polynucleic acid sequences resolved within a heteroduplex comprising;
a. preparing at least one heteroduplex polynucleotide; b. combining said heteroduplex polynucleotide with an effective amount of an agent or agents with at least exonuclease activity, polymerase activity, ligase activity and strand cleavage activity; and c. allowing sufficient time for the percentage of complementarity between strands of said heteroduplex polynucleotide to increase, wherein the ratio of polymerase activity to ligase activity is altered to obtain a desired length of resolution between the polynucleotide strands of the heteroduplex.
- 29. The method of claim 28 wherein said strand cleavage activity is a mismatch strand cleaving activity.
- 30. A method of generating mutations in a zone around a particular nucleotide within a desired polynucleotide comprising;
a. preparing at least one partially complementary polynucleotide having at least one non-complementary nucleotide within the zone around the desired polynucleotide, b. forming at least one heteroduplex between said desired polynucleotide and said partially complementary polynucleotide; c. combining said heteroduplex with at least one nucleotide analogue, effective amount of an agent or agents with exonuclease activity, polymerase activity, and mismatch strand cleavage activity; and d. allowing sufficient time for the nucleotide analogue to be incorporated into either said desired polynucleotide, said partially complementary polynucleotide or both.
- 31. The method according to claim 30 further comprising having a ligase activity.
- 32. A non-naturally occurring variant polynucleotide produced by the process of claim 1, 13, 18, 20 or 29.
- 33. The non naturally occurring variant polynucleotide of claim 32 having a desired functional property
- 34. A non-naturally occurring variant polypeptide produced by the process of claims 13, 18 or 20 having a desired functional property.
- 35. The non-naturally occurring polypeptide according to claim 34 wherein the desired functional property is different from a corresponding desired functional property of a polypeptide encoded by a parent polynucleotide.
- 36. A non-naturally occurring mutated polynucleotide produced by the process of claim 30.
- 37. The non-naturally occurring mutated polynucleotide according to claim 36 wherein the mutation is present at or within 30 nucleotides of a mismatch in the heteroduplex.
- 38. A non-naturally occurring variant polynucleotide comprising at least two parts, a first nucleotide sequence and a second nucleotide sequence,
wherein the first nucleotide sequence is identical to or complementary to part of a first naturally occurring polynucleotide, and not identical to and not complementary to a corresponding part of a second naturally occurring polynucleotide, wherein the second nucleotide sequence is identical to or complementary to part of a second naturally occurring polynucleotide, and not identical to and not complementary to a corresponding part of a first naturally occurring polynucleotide.
- 39. The non-naturally occurring variant polynucleotide of claim 38 further comprising a third nucleotide sequence wherein the third nucleotide sequence is identical to or complementary to part of a third naturally occurring polynucleotide and not identical to and not complementary to a corresponding part of the first naturally occurring sequence or the second naturally occurring sequence.
- 40. A non-naturally occurring variant polypeptide comprising at least two parts, a first peptide sequence and a second peptide sequence,
wherein the first peptide sequence is identical to or complementary to part of a first naturally occurring polypeptide, and not identical to and not complementary to a corresponding part of a second naturally occurring polypeptide, wherein the second peptide sequence is identical to or complementary to part of a second naturally occurring polypeptide, and not identical to and not complementary to a corresponding part of a first naturally occurring polypeptide.
- 41. The non-naturally occurring variant polypeptide of claim 40 further comprising a third peptide sequence wherein the third peptide sequence is identical to or complementary to part of a third naturally occurring polypeptide and not identical to and not complementary to a corresponding part of the first naturally occurring sequence or the second naturally occurring sequence.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. application Ser. No. 10/637,758, filed Aug. 8, 2003, which claims priority to U.S. Provisional Application No. 60/402,342, filed Aug. 8, 2002; U.S. application Ser. No. 10/226,372, filed Aug. 21, 2002, U.S. application Ser. No. 10/280,913 filed Oct. 25, 2002 and U.S. application Ser. No. 10/066,390, filed Feb. 1, 2002, which claims priority to U.S. Provisional Application No. 60/268,785, filed Feb. 14, 2001 and U.S. Provisional Application No. 60/266,386, filed Feb. 2, 2001, and all of which are incorporated herein by reference.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60402342 |
Aug 2002 |
US |
|
60268785 |
Feb 2001 |
US |
|
60266386 |
Feb 2001 |
US |
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
10637758 |
Aug 2003 |
US |
Child |
10684134 |
Oct 2003 |
US |
Parent |
10226372 |
Aug 2002 |
US |
Child |
10684134 |
Oct 2003 |
US |
Parent |
10280913 |
Oct 2002 |
US |
Child |
10684134 |
Oct 2003 |
US |
Parent |
10066390 |
Feb 2002 |
US |
Child |
10684134 |
Oct 2003 |
US |